Form 4: Teladoc Director Receives Equity Grant

Director Mark Douglas Smith was granted 30,441 restricted stock units by Teladoc Health, Inc. on May 21, 2026.

Summary

• Director Mark Douglas Smith received an award of 30,441 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Teladoc Health, Inc. (TDOC) common stock.
• The grant was issued on May 21, 2026, with a zero-dollar exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and settlement of these units.

Risks

• Market volatility affecting the future value of the underlying common stock.
• Vesting conditions tied to service or change of control events.

Future Outlook

The RSUs are scheduled to vest in full on May 21, 2027, or the day preceding the 2027 annual meeting, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation packages for S&P 500 and mid-cap healthcare technology companies.
• The one-year cliff vesting schedule is typical for annual director equity retainers.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future settlement of the units.

Next Steps

• Vesting of the 30,441 RSUs on May 21, 2027.

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Insider Transaction, Equity Compensation, Director Compensation